The MEB is preparing for Brexit

The United Kingdom has decided to leave the European Union. This has consequences for the regulation of medicines in Europe. The Medicines Evaluation Board (MEB) is preparing for the partial takeover of extra work which arises due to Brexit. In this context continuity is paramount. For that reason the Dutch government is investing € 2 million in extra capacity for the MEB in the coming years. Investments are also being made in reinforcing the European network by facilitating extra training opportunities.

Increased capacity

The MEB has set up by a project organisation to safeguard the continuity of the European network. Extra employees are currently being recruited and trained so that the Netherlands can take on some of the work.

Strengthening the European network

The Netherlands also wants to strengthen the regulatory network in Europe. The MEB is doing this by, for example, facilitating extra training opportunities for employees of other European medicines regulatory authoritiess. The aim is for this to lead to a better distribution of work between the medicines regulatory authorities of the European Member States.


The United Kingdom is leaving the European Union. The consequence of this is that regulatory work by the UK's Medicines and Healthcare products Regulatory Agency (MHRA - human) and the Veterinary Medicines Directorate (VMD) has to be taken over by regulatory authorities of other European Member States. In addition, the European Medicines Agency (EMA), which is currently located in London, has to relocate to another European Member State.